Clinical Trial Update: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) [Phase 2]

View source ↗

Summary

Clinical trial update on Phase 2 RGX-314 gene therapy for neovascular age-related macular degeneration, delivered in the suprachoroidal space, with the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• RGX-314

Snippet

Sponsor: AbbVie | Conditions: Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING